# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity

> **NCT07559136** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Overweight and Obesity

## Interventions

- **DRUG:** HRS9531 injection；Placebo
- **DRUG:** HRS9531 injection；Placebo
- **DRUG:** HRS9531 injection；Placebo

## Key facts

- **NCT ID:** NCT07559136
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-01
- **Final completion:** 2027-02
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07559136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07559136, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07559136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*